English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 3 March 2025, 15:41 JST
Share:
    

Source: Eisai
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
- Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine -

TOKYO, Mar 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the launch of the new nutritional drink “Chocola BB® Nightwell” (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3. The productbelongs to the Chocola BB brand, which supports people’s beauty and health, and will be available at pharmacy and drugstores throughout Japan.

Chocola BB Nightwell contains eight active ingredients, including vitamin B2, which supports fatmetabolism and converts it into energy, and glycine, which improves sleep quality associated with poornutrition, as well as herbal medicines (Crataegus oxyacantha and Citrus unshiu peel). With a grapefruit flavor, Chocola BB Nightwell is easy to drink, low in calories (5.1 kcal per bottle), and caffeine-free, allowing consumption before bedtime. By promoting fatigue recovery during sleep, Chocola BB Nightwell supports a refreshed start to the day.

Since the launch of Chocola BB tablets in 1952, the Chocola BB brand has been offering products forover 70 years to address various skin and fatigue symptoms, in line with the needs of each era. The current Chocola BB drink lineup consists of designated quasi-drugs for fatigue care, including “ChocolaBB® Light” for daily fatigue, “Chocola BB® Royal 2” for severe fatigue, and “Chocola BB® Hyper” for low vitality.

By marketing the Chocola BB series of products, Eisai is committed to addressing the diverse needswithin fatigue care, and supporting the beauty and wellness of even more people.

Please refer to the product’s website for details about Chocola BB Nightwell (Japanese only) www.eisai.jp/products/chocola/chocola_bb_nightwell

FOr more information, visit https://www.eisai.com/news/2025/news202514.html

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Friday, 27 March 2026, 20:14 JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
Friday, 27 March 2026, 18:19 JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Monday, 23 March 2026, 11:19 JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
Thursday, 19 March 2026, 10:54 JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
Tuesday, 17 March 2026, 19:49 JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
More news >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575